Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012

Sarepta Therapeutics to Present Company Overview at the Stifel Nicolaus 2012 Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. -stifel-nicolaus-2012-healthcare-conference.html
Published in Health and Fitness on Wednesday, August 29th 2012 at 5:45 GMT by Market Wire   Print publication without navigation


August 29, 2012 08:30 ET

Sarepta Therapeutics to Present Company Overview at the Stifel Nicolaus 2012 Healthcare Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwire - Aug 29, 2012) -  Sarepta Therapeutics (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Stifel Nicolaus 2012 Healthcare Conference in Boston, MA on Wednesday, September 5, 2012 at 3:50 p.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

The presentation will be webcast live under the events section of Sarepta Therapeutics' website at [ www.sareptatherapeutics.com ] and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources